Evidence map›Paper›PMID 30319249›Full record

ArticleInternational journal of chronic obstructive pulmonary disease

Comparison of the clinical characteristics and comprehensive assessments of the 2011 and 2017 GOLD classifications for patients with COPD in China.

Yu-He Hu, Zhen-Yu Liang, Li-Mei Xu, Wen-Hui Xu, Hao Liao, Rui Li, Kai Wang, Ying Xu, Chun-Quan Ou, Xin Chen

Open access · goldAbstract readComparative Study
In one paragraph

Article in International journal of chronic obstructive pulmonary disease. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
1.1field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 10 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. 2011 GOLD Stages of COPD: Transitions, Predictor Factors and Comparison with 2017 GOLD Stages.International journal of chronic obstructive pulmonary disease · 2020
    Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Yu-He HuDepartment of Respiratory Medicine, Zhujiang Hospital, Southern Medical University, Guangzhou, China, chen_xin1020@163.com.
Zhen-Yu LiangState Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
Li-Mei XuDepartment of Respiratory Medicine, Zhujiang Hospital, Southern Medical University, Guangzhou, China, chen_xin1020@163.com.
Wen-Hui XuDepartment of Respiratory Medicine, Zhujiang Hospital, Southern Medical University, Guangzhou, China, chen_xin1020@163.com.
Hao LiaoDepartment of Respiratory Medicine, Zhujiang Hospital, Southern Medical University, Guangzhou, China, chen_xin1020@163.com.
Rui LiDepartment of Respiratory Medicine, Zhujiang Hospital, Southern Medical University, Guangzhou, China, chen_xin1020@163.com.
Kai WangDepartment of Respiratory Medicine, Zhujiang Hospital, Southern Medical University, Guangzhou, China, chen_xin1020@163.com.
Ying XuDepartment of Respiratory Medicine, Zhujiang Hospital, Southern Medical University, Guangzhou, China, chen_xin1020@163.com.
Chun-Quan OuState Key Laboratory of Organ Failure Research, Department of Biostatistics, Guangdong Provincial Key Laboratory of Tropical Disease Research, School of Public Health, Southern Medical University, Guangzhou, China, ouchunquan@hotmail.com.
Xin ChenDepartment of Respiratory Medicine, Zhujiang Hospital, Southern Medical University, Guangzhou, China, chen_xin1020@163.com.
Zhujiang Hospital · CNSouthern Medical University · CNState Key Laboratory of Respiratory Disease · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveCompared with the 2011 Global Initiative for Chronic Obstructive Lung Disease (GOLD), there have been significant changes in the 2017 GOLD classification. The purpose of this study was to analyze the changes in clinical characteristics of the new A-B-C-D system and to explore its role in comprehensive assessment of COPD. SUBJECTS AND

methodsA total of 631 stable COPD patients were included in a cross-sectional survey. Data collected included baseline data and pulmonary function testing results, respiratory muscle strength, symptoms and quality of life, exercise capacity, nutritional status, and anxiety and depression as a comprehensive assessment. Based on the 2011 GOLD and 2017 GOLD classifications, patients were divided into Groups A

resultsIn the 2011 GOLD, 64 subjects in Group C

conclusionCompared with the 2011 GOLD, the 2017 GOLD reclassified more patients into Groups A and B, those with significantly worse lung function and higher BODE index. In the comprehensive assessment of the new classification, Groups B and D may have greater disease severity. However, the effectiveness of the new grading system in predicting patient prognosis, and its guidance on the use of drugs, remains to be explored in future studies.

Indexed as

Administration, InhalationAdrenal Cortex HormonesAgedAge FactorsBody Mass IndexBronchodilator AgentsChinaCross-Sectional StudiesDyspneaExercise ToleranceFemaleHumansMaleMiddle AgedPrognosisPulmonary Disease, Chronic ObstructiveAdrenal Cortex HormonesBronchodilator Agentscomprehensive assessmentCOPDGlobal Initiative for Chronic Obstructive Lung Disease

Identifiers

PMID30319249
PMCPMC6167996
OpenAlexW2892631311

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.